Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Endothelial growth factor receptor inhibition after radiotherapy.
Giovannini M, Gregorc V, Viganò MG, Spreafico A, Ghio D, Dell'Oca I, Bolognesi A, Villa E. Giovannini M, et al. Among authors: gregorc v. J Thorac Oncol. 2007 Jul;2(7):662. doi: 10.1097/JTO.0b013e318074de48. J Thorac Oncol. 2007. PMID: 17607125 Free article. No abstract available.
KRAS in NSCLC: State of the Art and Future Perspectives.
Cascetta P, Marinello A, Lazzari C, Gregorc V, Planchard D, Bianco R, Normanno N, Morabito A. Cascetta P, et al. Among authors: gregorc v. Cancers (Basel). 2022 Nov 4;14(21):5430. doi: 10.3390/cancers14215430. Cancers (Basel). 2022. PMID: 36358848 Free PMC article. Review.
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Cappuzzo F, Gregorc V, Rossi E, Cancellieri A, Magrini E, Paties CT, Ceresoli G, Lombardo L, Bartolini S, Calandri C, de Rosa M, Villa E, Crino L. Cappuzzo F, et al. Among authors: gregorc v. J Clin Oncol. 2003 Jul 15;21(14):2658-63. doi: 10.1200/JCO.2003.01.039. J Clin Oncol. 2003. PMID: 12860941 Clinical Trial.
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crinò L. Cappuzzo F, et al. Among authors: gregorc v. J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41. doi: 10.1093/jnci/djh217. J Natl Cancer Inst. 2004. PMID: 15292385 Clinical Trial.
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD. Cusatis G, et al. Among authors: gregorc v. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42. doi: 10.1093/jnci/djj469. J Natl Cancer Inst. 2006. PMID: 17148776
Role of computed tomography and [18F] fluorodeoxyglucose positron emission tomography image fusion in conformal radiotherapy of non-small cell lung cancer: a comparison with standard techniques with and without elective nodal irradiation.
Ceresoli GL, Cattaneo GM, Castellone P, Rizzos G, Landoni C, Gregorc V, Calandrino R, Villa E, Messa C, Santoro A, Fazio F. Ceresoli GL, et al. Among authors: gregorc v. Tumori. 2007 Jan-Feb;93(1):88-96. doi: 10.1177/030089160709300116. Tumori. 2007. PMID: 17455878 Clinical Trial.
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA Jr, Carbone DP. Taguchi F, et al. Among authors: gregorc v. J Natl Cancer Inst. 2007 Jun 6;99(11):838-46. doi: 10.1093/jnci/djk195. J Natl Cancer Inst. 2007. PMID: 17551144
114 results